emtricitabine / tenofovir disoproxil fumarate (Truvada®)

Following a full submission

AWMSG advice

Status: Superseded

AWMSG ADVICE SUPERSEDED BY AWMSG REVIEW ISSUED JUNE 2020. Refer to Provision of pre-exposure prophylaxis (PrEP) for HIV prevention in Wales for full details.

Provision of pre-exposure prophylaxis (PrEP) for HIV prevention in Wales (PDF, 59Kb)

Welsh Government written statement: All Wales study to provide Truvada to all those who would benefit from the preventative treatment (PDF, 38Kb)

Final Recommendation: emtricitabine-tenofovir (Truvada) 1625 (PDF, 373Kb)

Appraisal Report: emtricitabine-tenofovir (Truvada) 1625 (PDF, 306Kb)

Medicine details

Medicine name

emtricitabine / tenofovir disoproxil fumarate (Truvada®)

Formulation

200 mg/245 mg film-coated tablet

Reference number

1625

Indication

In combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk

Company

Gilead Sciences Ltd

BNF chapter

Infections

Assessment type

Full

Status

Superseded

Advice number

0817

NMG meeting date

08/03/2017

AWMSG meeting date

26/04/2017

Date of issue

11/09/2017

Date of last review

30/06/2020

Further information

AWMSG advice superseded by AWMSG review. See emtricitabine / tenofovir disoproxil page for full details.